When was 3D Medicines founded?

3D Medicines was founded in 2010.

Where is 3D Medicines located?

3D Medicines is headquartered in Pudong, China.

How many employees does 3D Medicines have?

As of Jun 30, 2026, the latest employee count at 3D Medicines is 67.

Where does 3D Medicines rank among its competitors?

3D Medicines ranks 152nd amongst 1812 active competitors, of which 92 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of 3D Medicines?

3D Medicines' top competitors include AbbVie, Amgen and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

3D Medicines - 2026 Company Profile, Funding & Competitors

3D Medicines is a public company based in Pudong (China), founded in 2010. It operates as a R&D company focused on manufacturing of drugs for multiple therapeutic areas. The company has 1812 active competitors, including 92 funded and 199 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.

Key Metrics

Founded Year

2010

Location

Pudong, China

Stage

Public

Investors

Efung Capital & 1 more

Ranked

152^nd among 1812 active competitors

Employee Count

67 as on Jun 30, 2026

Similar Companies

AbbVie & 1839 more

Exit Details

Public

View 3D Medicines' full profile

3D Medicines got listed on Dec 15, 2022.

Click here to take a look at 3D Medicines's IPO in detail

3D Medicines is a funded company. 3D Medicines has 2 institutional investors.

View details of 3D Medicines's funding rounds and investors

3D Medicines' employee count trend

3D Medicines has 67 employees as of Jun 26. Here is 3D Medicines's employee count trend over the years:

Uncover 3D Medicines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 3D Medicines include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of 3D Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Seaside Private Capital ... & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	70/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	69/100
152nd	3D Medicines 2010, Pudong (China), Public	R&D company focused on manufacturing of drugs for multiple therapeutic areas	-	Efung Capital & 1 others	38/100